Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.61 |
| ▸ | CDK4 | P11802 | 6/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | PLK1 | P53350 | 2/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 3/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.52 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.52 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684663 | 0.88 | CDK2 (0.78) | CDK2CDK4CCNE1KDRPLK1 | |
| SCHEMBL412401 | 0.83 | CDK2 (0.56) | CDK2CDK4CCNE1IGF1RCDK19 | |
| SCHEMBL411464 | 0.81 | CDK2 (0.75) | CDK2CDK4CCNE1KDRPLK1 | |
| SCHEMBL5138420 | 0.80 | CDK2 (0.53) | CDK2CDK4CCNE1PRKD3LCK | |
| SCHEMBL411956 | 0.80 | CDK2 (0.53) | CDK2CDK4CCNE1IGF1RCDK19 | |
| SCHEMBL5276382 | 0.80 | CDK2 (0.53) | CDK2CDK4CCNE1KDRIGF1R | |
| SCHEMBL415370 | 0.79 | CDK2 (0.52) | CDK2CDK4CCNE1KDRPLK1 | |
| SCHEMBL411836 | 0.79 | CDK2 (0.52) | CDK2CDK4CCNE1IGF1RCDK19 | |
| SCHEMBL413669 | 0.79 | MAPK8 (0.54) | CDK2CDK4CCNE1IRAK4 | |
| SCHEMBL413105 | 0.77 | MAPK13 (0.53) | CDK2CDK4CCNE1PRKD3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1694871-B | Imidazolopyridines and methods of making and using the same | BIOGEN IDEC INC | 2010-06-16 | — | — | CN | claimed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-06-22 | — | — | US | claimed |
| EP-1546112-A4 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| CN-1694871-A | Imidazolopyridines and methods of making and using the same | BIOGEN INC (US) | 2005-11-09 | — | — | CN | claimed |
| EP-1546112-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004021989-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| CN-1694871-B | Imidazolopyridines and methods of making and using the same | BIOGEN IDEC INC | 2010-06-16 | — | — | CN | disclosed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1546112-A4 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| CN-1694871-A | Imidazolopyridines and methods of making and using the same | BIOGEN INC (US) | 2005-11-09 | — | — | CN | disclosed |
| EP-1546112-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004021989-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | ALK, ACVR1, ACVRL1 | CDK2 515/4885CDK4 116/4885CCNE1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.